Abstract
Bone metastasis is frequently seen in NSCLC (non small-cell cancer )and have got poor prognosis. Bone is a hematopoietic organ and actively regulates our immune system. Nivolumab is a fully human IgG4 PD-1 ICI (immune checkpoint inhibitor) antibody, which disrupts PD-1 mediated signaling and restores antitumor immunity. We have studied the clinical outcome of Nivolumab monotherapy in NSCLC patients with bone metastasis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
